Linadex Indications/Uses

Multiple myeloma: Lenalidomide as combination therapy with Dexamethasone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Lenalidomide as combination therapy with Melphalan and prednisone is indicated for the treatment of ≥ 65 years old patients with previously untreated multiple myeloma who are not eligible for transplant.
Lenalidomide in combination with Dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have relapsed or have progressive disease after receiving at least one prior therapy.
Myelodysplastic syndromes: Lenalidomide as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Mantle cell lymphoma: Lenalidomide as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.